This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamazumi, T.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamazumi, T.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2000, p. 2883-2886, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

T. Yamazumi,dagger M. A. Pfaller,* S. A. Messer, A. Houston, R. J. Hollis, and R. N. Jones

Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242

Received 9 May 2000/Returned for modification 29 May 2000/Accepted 20 July 2000

The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of Cryptococcus neoformans. Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Overall, ravuconazole (MIC at which 90% of the isolates are inhibited [MIC90], 0.25 µg/ml) was more active than either itraconazole (MIC90, 0.5 µg/ml) or fluconazole (MIC90, 8 µg/ml). Among the isolates inhibited by >= 16 µg of fluconazole/ml, 90.2% were inhibited by <= 1 µg of ravuconazole/ml. On the basis of our findings and the favorable pharmacokinetic properties of ravuconazole, we suggest that ravuconazole may be useful for the treatment of infectious diseases due to C. neoformans and that further clinical studies to confirm these promising in vitro results are warranted.

* Corresponding author. Mailing address: Medical Microbiology Division, Department of Pathology, 606GH, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 384-9566. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu.

dagger Present address: Department of Clinical Pathology, Kinki University School of Medicine, Ohnohigashi, Osakasayama, Osaka, Japan 589-8511.

Antimicrobial Agents and Chemotherapy, October 2000, p. 2883-2886, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Sionov, E., Chang, Y. C., Garraffo, H. M., Kwon-Chung, K. J. (2009). Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence. Antimicrob. Agents Chemother. 53: 2804-2815 [Abstract] [Full Text]  
  • Yan, J.-H., Marino, M. R., Smith, R. A., Kanamaluru, V., O'Mara, E. M., Grasela, D. M. (2006). The Effect of Ravuconazole on the Pharmacokinetics of Nelfinavir in Healthy Male Volunteers. J Clin Pharmacol 46: 193-200 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Monzon, A., Rodriguez-Tudela, J. L. (2005). In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi. Antimicrob. Agents Chemother. 49: 5136-5138 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Kelaher, A., Sarafandi, A., Wuerthwein, G., Bacher, J., Walsh, T. J. (2005). Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. J Antimicrob Chemother 56: 899-907 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Doern, G. V., Diekema, D. J. (2005). Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43: 2163-2167 [Abstract] [Full Text]  
  • Trilles, L., Fernandez-Torres, B., dos Santos Lazera, M., Wanke, B., Guarro, J. (2004). In Vitro Antifungal Susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42: 4815-4817 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Rodriguez-Tudela, J. L. (2004). In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates. Antimicrob. Agents Chemother. 48: 3107-3111 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2004). Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of Candida spp.. J. Clin. Microbiol. 42: 3137-3141 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Lyman, C. A., Groll, A. H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N. A., Walsh, T. J. (2004). Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 48: 1188-1196 [Abstract] [Full Text]  
  • Maxwell, M. J., Messer, S. A., Hollis, R. J., Diekema, D. J., Pfaller, M. A. (2003). Evaluation of Etest Method for Determining Voriconazole and Amphotericin B MICs for 162 Clinical Isolates of Cryptococcus neoformans. J. Clin. Microbiol. 41: 97-99 [Abstract] [Full Text]  
  • Yamazumi, T., Pfaller, M. A., Messer, S. A., Houston, A. K., Boyken, L., Hollis, R. J., Furuta, I., Jones, R. N. (2003). Characterization of Heteroresistance to Fluconazole among Clinical Isolates of Cryptococcus neoformans. J. Clin. Microbiol. 41: 267-272 [Abstract] [Full Text]  
  • Clemons, K. V., Martinez, M., Calderon, L., Stevens, D. A. (2002). Efficacy of Ravuconazole in Treatment of Systemic Murine Histoplasmosis. Antimicrob. Agents Chemother. 46: 922-924 [Abstract] [Full Text]  
  • Kirkpatrick, W. R., Perea, S., Coco, B. J., Patterson, T. F. (2002). Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother 49: 353-357 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»